Paying for Cures: Creative Payment, Reimbursement, Market Access Models and Defining Value in the CGT Space

18 Jan 2023
Commercializing the Therapies of the Future Track

3:30pm Chair Introduction

Mark Truscheim, Strategic Director, MIT NEWDIGS


3:05pm Presentation: TBA

Kristin Viswanathan Wolff, Vice President, Market Access, bluebird bio


3:20pm Presentation: TBA

Senior Representative, Viralgen


3:35pm Presentation: TBA

Andrew Olaye, Executive Director, Market Access, Orchard Therapeutics


3:50pm Presentation: Defining value and global access pathways for gene therapies

• Demonstrating value of gene therapies within the current HTA context
• Scaling access models for 21st century medicines beyond traditional markets
• Must win integrated access capabilities to scale and commercialize

Tay Salimullah, Vice President, Head of Global Value and Access, Novartis Gene Therapies


4:05pm Closing Panel with Q&A

With all session participants 


Andrew Olaye
Executive Director, Market Access & Partnerships EMEA
Orchard Therapeutics
Mark Truscheim
Strategic Director, NEWDIGS Initiative Institute for Clinical Research and Health Policy Studies
Tufts Medical Center
Kristin Viswanathan Wolff
Vice President, Market Access
bluebird bio
Tay Salimullah
Vice President, Head of Global Value & Access, Novartis Gene Therapies